Studies of a Ras Antagonist in Breast Cancer
Annual rept. 8 Apr 2002-7 Apr 2003
VIRGINIA UNIV CHARLOTTESVILLE
Pagination or Media Count:
The aim of this project is preclinical testing of a novel Ras antagonist, farnesylthiosalicylate FTS in complex with a cyclodextrin CD carrier. Ras is involved in estrogen and growth factor signaling in breast cancer cells. inhibition of Ras should prevent growth of breast cancer cells. We have tested FTS-CD against several breast cancer cell lines in vitro and found that FTS-CD is effective against estrogen receptor positive breast cancer in vitro. FTS-CD is effective against Tamoxifen resistant cells in vitro. FTS-CD interferes with estrogen signaling. FTS-CD induces profound changes in cell signaling, manifested as increase in apoptosis and decrease in proliferation.
- Medicine and Medical Research